Oruka Therapeutics ORKA 深 滬
已收盤 11-06 16:00:00 美东时间
102.86
+6.840
+7.12%
華盛通- 最 高103.78
- 今 開97.99
- 成交量 107.14万股
- 最 低 96.05
- 昨 收 96.02
- 總市值 68.10亿
- 52周最高 115.515
- 市盈率 靜 --
- 換手率 1.62%
- 52周最低 25.23
- 委 比 -94.29%
- 總股本 6620.97万
- 歷史最高 5922.804
- 量 比 1.43
- 振 幅 8.05%
- 歷史最低 -0.636
- 每 手 1
- 風險率 26.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oruka Therapeutics to Participate in Multiple Upcoming Conferences
Oruka Therapeutics announced its participation in multiple upcoming conferences, including the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, the Stifel 2026 Healthcare Conference on November 11, 2026, the UBS Global Biopharma Conference on November 17, 2026, and the Jefferies Global Healthcare Conference on November 18, 2026. The company is focused on developing novel biologics for chronic skin diseases like plaque ...
11-03 12:00
美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
10-28 12:30
美股前瞻 | 伊朗释放和平信号！期指转涨油价回落；SK海力士盘前升逾3%，将于盘后放榜！
伊朗释放和平信号！期指转涨油价回落近1%，美债收益率下滑；SK海力士盘前升逾3%，将于盘后公布业绩；康宁、可口可乐、波音业绩齐发！汇丰控股盘前跌近7%>>
10-27 20:27
美股牛股 | Surgery Partners涨47.6%，获57亿美元私有化收购；山脉资源升17.7%，与EQT达成合并协议；Lumentum涨8.2%，获StoneX首次给予买入评级
Surgery Partners涨47.6%，获57亿美元私有化收购；山脉资源升17.7%，与EQT达成合并协议；Lumentum涨8.2%，获StoneX首次给予买入评级
10-27 16:28
Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026...
10-26 19:13
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oruka Therapeutics announced positive Week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001, a novel IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis. The high-dose group (600 mg) achieved 61% PASI 100 and 86% PASI 90, matching EVERLAST-A results. ORKA-001 showed favorable safety and tolerability, with no dose-dependent adverse events. The company plans to advance ORKA-001 into Phase 3 trials in 1H 2027, with 52-week ...
10-26 11:00
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
10-19 17:54
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Jaguar Health Stock Plunges Wednesday: What's Happening?
Jaguar Health Inc. (NASDAQ:JAGX) shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers. Jaguar Health stock is taking a hit today. What’s behind JAGX decline? Low-Float Volatility and Profit-Taking The sharp downward correction f...
09-23 22:31
